The observed data are (Y, S, Y τ , Z) where S ∈ {1, . . . , J} ∪ { }, and Y τ = 1 ⇒ Y = 1 by definition. Subjects with Y τ = 1 do not contribute any information about the relationship between Z, S, and Y , and hence the relevant observed data laws are P (Y, S, Y τ = 0, Z = 0) and P (Y, S, Y τ = 0, Z = 1). Functionals of these laws and their well-defined marginals are identified from the observed data. To simplify notation in the proofs which follow, we define P 0 = P (Y = 1, S, Y τ = 0, Z = 0) and P 1 = P (Y = 1, S, Y τ = 0, Z = 1), which are identifiable from placebo and vaccine recipients, respectively. We will also refer to the identifiable marginal P (S 1 , Y τ 1 = 0) often in what follows, denoting it P S 1 or P S 1 =j when S 1 takes on a particular value j.
Proof of Proposition 1
By SUTVA and Ignorable Treatment Assignments ([A1]-[A2]), the observed laws satisfy P 0 = P (Y 0 = 1, S 0 , Y τ 0 = 0) and P 1 = P (Y 1 = 1, S 1 , Y τ 1 = 0). When [CB] is true, these can be further simplified to P 0 = P (Y 0 = 1, Y τ 0 = 0) and P 1 = P (Y 1 = 1, S 1 , Y τ 1 = 0)
Now, note that
Since (Y τ 1 , S 1 , Y 1 ) are unknown for placebo subjects and Y τ 0 is unknown for vaccinated subjects, neither P (Y 1 = 1, S 1 , Y τ 1 = 0, Y τ 0 = 1) nor P (S 1 , Y τ 1 = Y τ 0 = 0) is identifiable in (2). Similarly, in (3), P (Y 0 = 1, Y τ 1 = 1, Y τ 0 = 0) and P (S 1 = j, Y τ 1 = Y τ 0 = 0) are nonidentifiable. So 2J parameters must be specified to identify the J possible values of R 1 (S 1 ) and the J possible values of R 0 (S 1 ).
Since R m 1 (S 1 ) = P 1 /P S 1 , with both elements of the fraction identifiable, R m 1 is identifiable.
Hence J parameters must be specified to identify R m 0 .
Proof of Proposition 2
is determined by the remaining J − 1 values. Hence the number of parameters required to specify the J values of R 0 is J − 1.
Proof of Proposition 3
Note that R m 0 (S 1 ) equals
Hence R m 0 would be identifiable from the observed data if we could identify P (Y 0 = 0, S 1 , Y τ 1 = 0). {Y 0 = 0} ⊂ {Y τ 0 = 0} and [A3 ] together imply that this probability is proportional to
[A6] guarantees that this probability is equal to P (S 1 | Y 0 = 0). Note that identifiability can be achieved under the assumption of equality in distribution (rather than almost surely) of S 1 and S c 1 among those with Y 0 = Y c 0 = 0; however, this weaker assumption does not guarantee the unbiasedness of our proposed regression-based estimators, where S c 1 values are used in place of S 1 .
Closeout provides no additional information about the relationship between Y 1 and S 1 , hence J parameters are still required to identify R 1 . For R 0 , we have
While closeout (and [A5]-[A6]) enables the numerator to be identified, the denominator is a function of J − 1 nonidentifiable parameters (recall equation (5)) and it is immediate that J − 1 parameters are required to describe the values of R 0 (S 1 ).
Appendix B: Likelihood terms
Let the observed data be O
as described in the main manuscript. We describe the form of the likelihood under [CB],
[A1]-[A3 ], and [A5]-[A6]. The likelihood takes the form
(note that, by [A6], the indicator of infection during the closeout period Y c does not factor into the likelihood; if [A6] is relaxed, then the likelihood will include an additional term for placebo recipients who remain uninfected at the end of the trial but are infected during the subsequent closeout period).
The a term corresponds to vaccine recipients with S 1 measured:
The term involving c is active for placebo recipients who are closed out, and hence have S c 1 measured. We can write
be factored out of the likelihood.
The second term, involving b, is relevant for placebo recipients who are infected prior to the end of the trial and hence are not eligible to be closed out. Their likelihood contribution is therefore integrated over all possible values of
For low-dimensional S 1 and W , empirical estimates of the nuisance parameters F S 1 |Y τ 1 =0,W and P (Y τ 0 = 0 | Y τ 1 = 0, W ) can be derived from observed data and plugged into the likelihood; if S 1 and/or W are continuous, semiparametric or parametric estimation methods may be preferable.
The preceding development assumes that S 1 is measured from all subjects who are vaccinated and have Y τ = 0, and S c 1 is obtained from all placebo recipients who remain uninfected and are closed out at the end of the trial. In reality, it will usually be too costly and/or time-consuming to perform the required assays on such a substantial fraction of the study population. Case-cohort sampling, in which all (or most) infected vaccine recipients and a sub-sample of uninfected vaccine and (closed-out) placebo recipients are selected to have S 1 or S c 1 measured, will often be performed in practice due to cost and time constraints.
As explicitly addressed in GH, this sampling scheme can be easily accommodated in the estimated likelihood framework.
Appendix C: Relationships between joint and marginal risks
Let [CB] hold, and define the quantities
We seek to show the results from display (12) in the main manuscript:
To prove (24), we have
Now, to prove (25), we have
QED Appendix D: Restricting sensitivity parameters
A number of conditions constrain the range of sensitivity parameter values which we consider in our sensitivity analysis. These conditions are of two main types: 1) Equalities which the sensitivity parameters (and estimands of interest) must satisfy in terms of observable quantities, and 2) Inequalities derived by combining these equalities with the requirement that probabilities must be bounded between 0 and 1.
Equalities
where θ τ Z , θ Z , and F S 1 |Y τ 1 =0 are identifiable from vaccine trial data. Further, if [A5] holds and, then with η
where
are identifiable from vaccine trial data when closeout vaccination is performed.
Inequalities
Combining the equalities with the given assumptions and the requirement that probabilities take values between 0 and 1 restricts the range of possible sensitivity parameter values. For example, the requirement that 0 R 0 (s), R 1 (s) 1 implies the inequalities
Additional inequalities can be derived when S is binary, as in our simulations. When S 1 ∈ {1, 2}, we have
and hence we can sharpen the lower bound of π(s).
These constraints may allow investigators to use available data to suggest plausible sensitivity parameter values. Further restrictions may be derived based on scientific knowledge; for example, one might assume a type of monotonicity condition whereby higher (lower) values of S 1 lead to lower (higher) clinical risk. We do not pursue those extensions here.
Appendix E: Proportion of Treatment Explained and Relative Effect
The P T E and RE are estimated by fitting the following regression models from observed data:
From these models, we compute P T E = 1 − β 1 β 0 and RE = β 0 β 2 . The motivation for and properties of P T E and RE are discussed at length in Burzykowski et al. (2005) ; models (43)-(45) are suggested in Buyse and Molenberghs (1998) . Since S is only defined if Y τ = 0, models (44)-(45) can only be fitted using data from subjects not infected prior to τ ; though we may fit model (43) from either this subgroup or from all subjects, for simplicity we choose the former. Table 2 Parameter settings for simulations to compare performance of surrogate value assessment methods. SV = surrogate value scenario, SB = amount of pre-τ selection bias. θ τ z = P (Y τ z = 1), θz = P (Yz = 1).
For Table 3 , main manuscript: Table 3 Operating characteristics of P T E, RE, and sensitivity analyses in simulated trials of size n = 10, 000, when P (Y τ 1 = 1) = 0.05. SV = surrogate value scenario, SB = amount of pre-τ selection bias. For P T E and RE, we report P T E med and RE med , the median point estimates over 500 simulations, along with the Monte Carlo standard error (σ). For the sensitivity analysis, each simulation yields 64 estimates of ∆1 and ∆2 from which the minimum, median, and maximum values are computed. (Min,Med,Max) [Rng] gives the medians of these three order statistics and the median range over 500 simulations. M SIW = Median Sensitivity Interval Width, where the sensitivity interval is the union of the Wald confidence intervals for all the sensitivity parameter settings, using Monte Carlo standard errors computed over the 500 simulations. 
